Furthermore, CalciMedica developed a selective Orai1 inhibitor, termed AuxoraTM, that showed a safety profile and tolerability in a Phase 2b clinical trial for the treatment of acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS) [234,235]. The gene discussed is ORAI1; the disease is acute pancreatitis.